Standout Papers

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label... 2020 2026 2022 2024402
  1. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial (2020)
    Shukui Qin, Zhenggang Ren et al. The Lancet Oncology

Immediate Impact

7 from Science/Nature 58 standout
Sub-graph 1 of 21

Citing Papers

Hepatocellular carcinoma: signaling pathways and therapeutic advances
2025 Standout
Management of Fatigue in Adult Survivors of Cancer: ASCO–Society for Integrative Oncology Guideline Update
2024 Standout
1 intermediate paper

Works of Xiaoyan Lin being referenced

Effects of a Mind Map–Based Life Review Program on Anxiety and Depressive Symptoms on Cancer Patients Undergoing Chemotherapy
2020
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
2020 Standout

Author Peers

Author Last Decade Papers Cites
Xiaoyan Lin 564 274 169 319 77 1.0k
Wenju Chang 510 278 299 191 77 1.2k
Chang‐Fang Chiu 346 147 105 195 62 1.0k
Kun‐Ming Rau 443 336 241 255 63 1.2k
Samantha M. Ruff 286 210 251 203 82 876
Kathryn Field 525 318 135 115 75 1.2k
Jing Lin 196 210 157 144 69 1.2k
Chun‐Shu Lin 293 349 348 354 83 1.4k
Angelica Petrillo 527 335 224 131 68 1.1k
Zhenhua Hu 369 129 272 240 60 998
Daniel Motola‐Kuba 460 301 220 167 48 1.2k

All Works

Loading papers...

Rankless by CCL
2026